Poorly controlled postoperative pain: prevalence, consequences, and prevention

• Published in: Journal of pain research 2017-01, Vol.10, p.2287-2298
• Main Author: Gan, Tong J
• Format: Article
• Language: English
• Subjects: acute pain; Analgesics; Back surgery; chronic pain; Complications and side effects; Joint surgery; Ligands; Morbidity; Narcotics; opioid; Pain management; Patient satisfaction; Postoperative pain; Prevention; Proteins; Quality of life; Review; Risk factors; Studies; Surgery; surgical procedures
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S144066

This review provides an overview of the clinical issue of poorly controlled postoperative pain and therapeutic approaches that may help to address this common unresolved health-care challenge. Postoperative pain is not adequately managed in greater than 80% of patients in the US, although rates vary depending on such factors as type of surgery performed, analgesic/anesthetic intervention used, and time elapsed after surgery. Poorly controlled acute postoperative pain is associated with increased morbidity, functional and quality-of-life impairment, delayed recovery time, prolonged duration of opioid use, and higher health-care costs. In addition, the presence and intensity of acute pain during or after surgery is predictive of the development of chronic pain. More effective analgesic/anesthetic measures in the perioperative period are needed to prevent the progression to persistent pain. Although clinical findings are inconsistent, some studies of local anesthetics and nonopioid analgesics have suggested potential benefits as preventive interventions. Conventional opioids remain the standard of care for the management of acute postoperative pain; however, the risk of opioid-related adverse events can limit optimal dosing for analgesia, leading to poorly controlled acute postoperative pain. Several new opioids have been developed that modulate μ-receptor activity by selectively engaging intracellular pathways associated with analgesia and not those associated with adverse events, creating a wider therapeutic window than unselective conventional opioids. In clinical studies, oliceridine (TRV130), a novel μ-receptor G-protein pathway-selective modulator, produced rapid postoperative analgesia with reduced prevalence of adverse events versus morphine.